Celebrating our 100th founding anniversary: 5-Year Growth Strategy with a 10-Year Vision
05 | Corporate
Fumihisa Hirose,
General Manager, Strategic Planning Dept. and CTO
Safe Harbor for Forward-Looking Statements and Use of Document
Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.
The market share information in this presentation is partly derived from our own independent research.
Information about products (including products currently in development) which is included in this material is not intended to constitute an advertisement or medical advice.
Terumo Corporation
Investor Relations Dept.
E-mail: kouhou_terumo01@terumo.co.jp
©TERUMO CORPORATION | 2 / 17 |
Celebrating our 100th founding anniversary: 5-Year Growth Strategy with a 10-Year Vision
GS26 FY22~26
Strengthen existing businesses and firmly invest in the future
FY27~31
Strengthen corporate foundation and generate solid profit from high- growth businesses
FY32~
Lead paradigm shift in medical care and make a leap toward a "New Terumo"
Company
Corporate
Strengthen existing
businesses
Establish and accelerate high-growth businesses
Explore new business opportunities (innovation)
Strengthen corporate foundation (innovation, human resources, profitability
improvement, production, ESG/CSV)
©TERUMO CORPORATION | 3 / 17 |
Vision for the Next 10 Years
From Devices
To Solutions
Focus in solutions: The 3Ds
01
Delivery
High value-added biological access and delivery for advanced medical care
02 | 03 |
Digital | DeviceuticalsTM |
Disease-based approach | Maximize drug effectiveness through |
focused on improving long-term | innovative devices |
patient QOL (Patient Journey) |
©TERUMO CORPORATION | 4 / 17 |
01
Delivery
High value-added biological access and delivery for advanced medical care
Penetration rate of minimally invasive therapy
60% or less
- The penetration rate of minimally invasive medicine is still low except for a few diseases
- Aspiring for a world with 100% minimally invasive therapy
Source: JAMA Surg. 2015;150(2):169-172, etc.
©TERUMO CORPORATION
Pursue vascular delivery
Deliver treatment to areas and cases that were previously difficult to reach
5 / 17
Pioneer new treatment routes including nonvascular routes
Develop new treatments through completely different routes
Treat with accuracy and precision
Use technology to pinpoint lesions for treatment
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Terumo Corporation published this content on 16 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 December 2021 04:28:05 UTC.